Emgality® achieves primary and secondary outcomes in Phase III trial for migraines

Written by Sharon Salt, Editor

Eli Lilly and Company (Basingstoke, UK) have announced that Emgality® (galcanezumab) has met the primary and all key secondary outcomes in a Phase III clinical trial evaluating the efficacy and safety of the drug (the CONQUER study). CONQUER was a Phase III, double-blind, global study conducted in 12 countries, which enrolled 462 people with chronic migraine (n = 193) or episodic migraine (n = 269) who had a documented history of treatment failures on two to four different standard-of-care migraine preventive medication categories. Treatment failures were identified as 1) inadequate efficacy after at least 2 months of treatment at the...

To view the full article, please register now for access

It's completely free